Various adjuncts have been used with local anesthetics in spinal anesthesia to provide good quality of intra-operative and better post-operative analgesia. Dexmedetomidine is a new α-2 adrenergic agonist, now being used as a neuraxial adjuvant. The aim of our study was to investigate the effect of intrathecal administration of dexmedetomidine 5 μg and 10 μg, as an adjuvant to bupivacaine 0.5%, on the onset and duration of sensory and motor block, the hemodynamic effects, the duration of analgesia and the occurrence of side effects. Methodology: This prospective randomized double blind study included 90 patients. Patients were randomly allocated into three groups of 30 patients each. Group B received 15 mg of 0.5% hyperbaric bupivacaine with normal saline, group D1 received 15 mg of hyperbaric bupivacaine with 5 μg and group D2 received 15 mg of hyperbaric bupivacaine with 10 μg of dexmedetomidine with normal saline to a total volume of 3.5 ml. The onset and duration of sensory and motor block, the hemodynamic effects, the duration of analgesia and the occurrence of side effects were noted. Results: The mean time taken for the sensory block to reach T10 dermatome and motor block to reach Bromage 3 grade was significantly rapid in D1 and D2 groups as compared to bupivacaine group. The time taken for regression of sensory block to S1 dermatome and Bromage 0 motor block and the time to first rescue analgesic were increased significantly by addition of dexmedetomidine in a dose dependent manner. Conclusion: Dexmedetomidine added to hyperbaric bupivacaine intrathecally has a dose dependent favorable effect on the onset and regression of sensory and motor block.